Ghost Tree Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

Ghost Tree Capital’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$7.67M	Sell	150,000 -90,000	-38%	-$4.64M	2.32%	16
2024 Q2	$10.7M	Buy	240,000 +40,000	+20%	+$1.85M	3.37%	9
2024 Q1	$9.36M	Buy	200,000 +135,000	+208%	+$5.28M	2.59%	10
2023 Q4	$2.31M	Sell	65,000 -36,443	-36%	-$1.12M	0.76%	38
2023 Q3	$3.02M	Buy	+101,443	New	+$2.09M	0.99%	34
2022 Q2	–	Sell	-85,000	Closed	-$1.87M	–	38
2022 Q1	$1.87M	Sell	85,000 -33,344	-28%	-$675K	0.4%	34
2021 Q4	$3.36M	Sell	118,344 -31,656	-21%	-$780K	1.2%	32
2021 Q3	$3.16M	Sell	150,000 -93,309	-38%	-$1.95M	0.92%	41
2021 Q2	$4.59M	Buy	+243,309	New	+$4.28M	1.26%	29

Other funds holding CRNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Ghost Tree Capital's CRNX Position: Q3 2024 in Review

Ghost Tree Capital reduced its Crinetics Pharmaceuticals (CRNX) stake by 38% in Q3 2024, selling an estimated $4.64M and leaving 150,000 shares worth $7.67M. The position accounts for 2.32% of the portfolio, ranked #16.

Ghost Tree Capital first reported a position in CRNX in Q2 2021 and has held it in 9 quarters since. The position peaked at $10.7M in Q2 2024. 235 funds tracked by Wall St. Rank hold CRNX as of Q3 2024.

Ghost Tree Capital held 150,000 shares of Crinetics Pharmaceuticals worth $7.67M as of Q3 2024.
Ghost Tree Capital sold 90,000 Crinetics Pharmaceuticals shares in Q3 2024, an estimated $4.64M.
Crinetics Pharmaceuticals made up 2.32% of Ghost Tree Capital's portfolio in Q3 2024, its #16 holding.
Ghost Tree Capital first reported a position in Crinetics Pharmaceuticals in Q2 2021 and has held it in 9 quarters since.
Ghost Tree Capital's Crinetics Pharmaceuticals position peaked at $10.7M in Q2 2024.
235 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.